

John Fanikos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4415469/publications.pdf>

Version: 2024-02-01

95
papers

2,296
citations

257450

24
h-index

223800

46
g-index

97
all docs

97
docs citations

97
times ranked

3367
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of Pharmacy Executive Quality and Safety Walkrounds at a Tertiary Academic Medical Center. <i>Hospital Pharmacy</i> , 2022, 57, 211-216.	1.0	1
2	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	3.4	4
3	Characteristics of the ideal clinical pharmacy residency candidate: A survey of residency program directors and preceptors in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 66-71.	2.7	0
4	Cost-effectiveness of andexanet-alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. <i>Journal of Medical Economics</i> , 2022, 25, 309-320.	2.1	6
5	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
6	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	2.1	3
7	Management of a parenteral opioid shortage using ASHP guidelines. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 426-435.	1.0	2
8	ASHP Guidelines on Medication-Use Evaluation. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 168-175.	1.0	10
9	Cleveland Clinic International IV Robotics Summit. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 800-805.	1.0	2
10	Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1568-1575.	1.0	4
11	Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1290-1299.	2.8	65
12	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.	2.1	0
13	Non-Sterile to Sterile Compounding: An Unconventional Response During the COVID-19 Pandemic. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110178.	1.0	0
14	Opioid-Free Recovery After Hernia Repair with HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting: A Randomized, Open-Label Study. <i>Pain and Therapy</i> , 2021, 10, 1295-1308.	3.2	6
15	The Pharmacist Discharge Care (PHARM-DC) study: A multicenter RCT of pharmacist-directed transitional care to reduce post-hospitalization utilization. <i>Contemporary Clinical Trials</i> , 2021, 106, 106419.	1.8	8
16	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. <i>Blood Advances</i> , 2021, 5, 5283-5289.	5.2	1
17	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42
18	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. <i>Thrombosis and Haemostasis</i> , 2020, 120, 027-035.	3.4	35
20	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1163-1170.	1.6	9
21	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice (1995)</i> , 2020, 48, 1-11.	1.0	9
22	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.	2.1	0
23	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2060-2072.	2.8	230
24	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.5	1
25	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	1.5	18
26	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. <i>Journal of Clinical Lipidology</i> , 2020, 14, 315-321.e4.	1.5	1
27	Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review. <i>International Journal of Pharmaceutical Compounding</i> , 2020, 24, 346-351.	0.0	0
28	Use of P2Y12 inhibitors among Medicaid beneficiaries between 2008 and 2018. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 539-541.	2.1	0
29	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	1.5	0
30	Why Does the Food and Drug Administration Need to Ban Kratom?. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 169-174.	1.5	1
31	Kratom from Head to Toe—Case Reviews of Adverse Events and Toxicities. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 141-168.	1.5	24
32	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.	1.7	20
33	Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 111-117.	1.5	3
34	“Inactive” ingredients in oral medications. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	68
35	Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 537-542.	1.0	2
36	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. <i>New England Journal of Medicine</i> , 2019, 380, 1606-1617.	27.0	266

#	ARTICLE	IF	CITATIONS
37	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. <i>Open Forum Infectious Diseases</i> , 2019, 6, S5-S5.	0.9	0
38	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2019, 132, 16-24.	1.5	5
39	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 331-335.	2.1	3
40	Unfractionated Heparin and Low-Molecular-Weight Heparin. , 2018, , 31-57.		4
41	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.	1.5	3
42	Intravenous and Oral Hyperammonemia Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 182-193.	1.5	0
43	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.	1.4	7
44	Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety. <i>Journal of General Internal Medicine</i> , 2018, 33, 2005-2007.	2.6	3
45	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 1015-1023.	1.5	38
46	The Reply. <i>American Journal of Medicine</i> , 2017, 130, e365-e366.	1.5	1
47	An assessment of currently available i.v. push medication delivery systems. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e230-e235.	1.0	4
48	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. <i>American Journal of Medicine</i> , 2017, 130, 1137-1143.	1.5	7
49	Best Practices for Medication Utilization Evaluations in Postsurgical Pain Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2017, 5, 33-40.	1.5	2
50	Prescribing Naloxone: Managing and Preventing Opioid-Related Overdoses. <i>Current Emergency and Hospital Medicine Reports</i> , 2017, 5, 11-15.	1.5	0
51	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , 2017, 40, 46-52.	1.8	25
52	Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 132-135.	0.7	3
53	Assessment of the Impact of Nursing Interruptions on Pharmacist Workflow and Efficiency. <i>Hospital Pharmacy</i> , 2016, 51, 49-53.	1.0	0
54	Patient-Reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Anti-inflammatory Drug, Opioids, or Both. <i>Academic Emergency Medicine</i> , 2016, 23, 331-341.	1.8	15

#	ARTICLE	IF	CITATIONS
55	The frequency of inappropriate nonformulary medication alert overrides in the inpatient setting. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 924-933.	4.4	14
56	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	1.5	24
57	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. <i>American Journal of Medicine</i> , 2016, 129, S89-S96.	1.5	12
58	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. <i>American Journal of Emergency Medicine</i> , 2016, 34, 46-51.	1.6	16
59	Regulatory Impact on Thrombosis Treatment, Prevention, and Anticoagulant Use. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1115-1135.	2.2	2
60	Invited Commentary: Initial Experience with Direct Oral Anticoagulants in the Perioperative Setting. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 88-92.	1.5	0
61	Reversal agents for use with direct and indirect anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s27-s48.	1.0	20
62	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.	1.5	121
63	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 15-31.	2.1	108
64	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. <i>Journal of Atrial Fibrillation</i> , 2016, 9, 1481.	0.5	5
65	Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2015, 90, E143-5.	4.1	7
66	Regulatory, legislative, and policy updates with anticoagulant use. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 273-287.	2.1	0
67	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , 2015, 75, 1627-1644.	10.9	37
68	Medication Use Evaluation: Pharmacist Rubric for Performance Improvement. <i>Pharmacotherapy</i> , 2014, 34, 5S-13S.	2.6	13
69	Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy</i> , 2013, 33, 1191-1198.	2.6	7
70	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 83-97.	1.5	133
71	Submassive Pulmonary Embolism: Risk Evaluation and Role of Fibrinolysis. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 236-246.	1.5	0
72	Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 226-235.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Hospital Costs of Acute Pulmonary Embolism. American Journal of Medicine, 2013, 126, 127-132.	1.5	103
74	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. Journal of Medical Economics, 2013, 16, 1190-1192.	2.1	0
75	Thrombosis in Suspected Heparin-induced Thrombocytopenia Occurs More Often with High Antibody Levels. American Journal of Medicine, 2012, 125, 44-49.	1.5	55
76	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. American Journal of Medicine, 2012, 125, 258-264.	1.5	45
77	Anticoagulation-associated Adverse Drug Events. American Journal of Medicine, 2011, 124, 1136-1142.	1.5	92
78	Venous Thromboembolism Prophylaxis for Medical Service "Mostly Cancer" Patients at Hospital Discharge. American Journal of Medicine, 2011, 124, 1143-1150.	1.5	12
79	Efficacy and safety of novel anticoagulants compared with established agents. Therapeutic Advances in Hematology, 2011, 2, 175-195.	2.5	13
80	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. Blood, 2011, 118, 2062-2062.	1.4	4
81	Adherence to Pharmacological Thromboprophylaxis Orders in Hospitalized Patients. American Journal of Medicine, 2010, 123, 536-541.	1.5	55
82	Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias. American Journal of Health-System Pharmacy, 2009, 66, 2189-2197.	1.0	3
83	Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thrombosis and Haemostasis, 2009, 102, 688-693.	3.4	59
84	Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thrombosis and Haemostasis, 2008, 100, 1130-1135.	3.4	44
85	Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals. American Journal of Health-System Pharmacy, 2007, 64, 2037-2043.	1.0	10
86	Impact of Smart Infusion Technology on Administration of Anticoagulants (Unfractionated Heparin, Low-Molecular-Weight Heparin, and Direct Thrombin Inhibitors) in a Large Academic Medical Center. American Journal of Health-System Pharmacy, 2007, 64, 2044-2050.	1.0	42
87	Adverse Drug Events in Hospitalized Cardiac Patients. American Journal of Cardiology, 2007, 100, 1465-1469.	1.6	38
88	Risk Factors for the Assessment of Patients with Pulmonary Embolism. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 871-880.	4.9	3
89	Major Bleeding Complications in a Specialized Anticoagulation Service. American Journal of Cardiology, 2005, 96, 595-598.	1.6	65
90	Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. American Journal of Cardiology, 2004, 93, 247-250.	1.6	61

#	ARTICLE	IF	CITATIONS
91	Medication errors associated with anticoagulant therapy in the hospital. American Journal of Cardiology, 2004, 94, 532-535.	1.6	62
92	Total Parenteral Nutrition Preparation for a Known Latex-Allergic Patient. Hospital Pharmacy, 2001, 36, 746-749.	1.0	0
93	Visual Compatibility of Famotidine with Commonly used Critical-care Medications During Simulated Y-site Injection. American Journal of Health-System Pharmacy, 1988, 45, 1556-1557.	1.0	0
94	Visual compatibility of perphenazine with various antimicrobials during simulated Y-site injection. American Journal of Health-System Pharmacy, 1987, 44, 574-575.	1.0	0
95	Stability of bacitracin solution frozen in glass vials or plastic syringes. American Journal of Health-System Pharmacy, 1987, 44, 1125-1127.	1.0	0